Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) EBT (2016 - 2023)

Rapid Therapeutic Science Laboratories' EBT history spans 8 years, with the latest figure at $46422.0 for Q2 2023.

  • For Q2 2023, EBT rose 226.02% year-over-year to $46422.0; the TTM value through Jun 2023 reached $59556.0, up 101.74%, while the annual FY2022 figure was -$1.8 million, 37.42% up from the prior year.
  • EBT for Q2 2023 was $46422.0 at Rapid Therapeutic Science Laboratories, down from $191271.0 in the prior quarter.
  • Across five years, EBT topped out at $191271.0 in Q1 2023 and bottomed at -$1.6 million in Q1 2022.
  • The 5-year median for EBT is -$311148.0 (2020), against an average of -$471084.7.
  • The largest annual shift saw EBT crashed 719.97% in 2020 before it skyrocketed 226.02% in 2023.
  • A 5-year view of EBT shows it stood at -$176690.0 in 2019, then crashed by 759.17% to -$1.5 million in 2020, then grew by 19.98% to -$1.2 million in 2021, then skyrocketed by 104.03% to $48939.0 in 2022, then dropped by 5.14% to $46422.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's EBT are $46422.0 (Q2 2023), $191271.0 (Q1 2023), and $48939.0 (Q4 2022).